Ştiinţe Medicale - Academia de Ştiinţe a Moldovei

Ştiinţe Medicaleand risk of stroke in patients with asymptomatic internal-carotid-arterystenosis. North American Symptomatic CarotidEndarterectomy Trial Collaborators. N. Engl. J. Med., 2000;342:1693–1700.10. Grosu A. Fibrilaţia atrială, Chișinău, 2006, p. 22,64.11. Watson T., Shantsila E., Lip G. Y. Mechanisms ofthrombogenesis in atrial fibrilla tion: Virchow’s triad revisited.Lancet, 2009; 373:155–166.12. Al-Saady N. M., Obel O. A., Camm A. J. The leftatrial appendage: structure, function and role in thromboembolism,Heart., 1999; vol. 82:547-555.13. Roldan V., Marin F., Marco P. et al. Hypofibrinolysisin atrial fibrillation, Amer. Heart J. – 1998, vol.136:956-960.14. Goldsmith I., Blann A.D., Patel R.L. et.al. Reducedindices of left atrial hypercoagulability in patients with severemitral regurgitation. Amer. J. Cardiology, 2000, vol. 86:234-236.15. Fuster V., Ryden L., Asinger R. et al. ACC/AHA/ESC Guidelines for the management of patients with atrialfibrillation: executive summary. Circulation, 2001, vol.104:2118-2150.16. Sacco R.L., Adams R., Albers G. et al. Guidelinesfor prevention of stroke in patients with ischemic stroke ortransient ischemic attack. Stroke, 2006; 37:577-617.17. Akdemir I., Dagdelen S., Yuce M. et al. Silent braininfarction in patients with rheumatic mitral stenosis. Jpn.Heart. J., 2002; 43:137-44.18. Vahanian A., Baumgartner H., Bax J. et al. Guidelineson the management of valvular heart disease: the TaskForce on the Management of Valvular Heart Disease of theEuropean Society of Cardiology. Eur. Heart. J. 2007; 28:230–268.19. Mylonakis E., Calderwood S.B. Infective endocarditisin adults. N. Engl. J. Med., 2001, 345:1318-1330.20. Matcher D.B. et al. Medical treatment for stroke prevention.Annals of Int. Med., 1994; 121(1):54-55.21. Predictors of major vascular events in patients withtransient ischaemic attack or minor stroke and non-rheumaticatrial fibrillation. EAFT Study Group. Stroke, 1995,vol.26:801-806.22. Vermeer Se et al. Asymptomatic stroke. Lancet Neurol.,2007; 6:611-9.23. Dickstein K., Cohen-Solal A., Filippatos G. et al.ESC Guidelines for the diagnosis and treatment of acute andchronic heart failure 2008. Eur. Heart. J., 2008; 29:2388–2442.24. Stroke in AF working group. Independent predictorsof stroke in patients with atrial fibrillation: a systematicreview. Neurology., 2007; 69:546–554.25. Autors/ Task Force Members: A. John Camn, PaulusKirchhof, Gregory Y. H. Lip Guidelines for the managementof atrial fibrillation. European Heart. J., 2010; 31:2369-2429.26. Шевченко О.П. Артериальная гипертония ицеребральный инсульт.М: Реафарм 2001; 191.27. Taylor A.J., Kent S.M., Flaherty P.J. et al. ARBITER:Arterial Biology for the Investigation of the Treatment Effects51of Reducing Cholesterol: a randomized trial comparing theeffects of atorvastatin and pravastatin on carotid intima medialthickness. Circulation, 2002; 106:2055-60.28. Д.В. Преображенский. Инсульт и другиетромбоэмболические осложнения при мерцаниипредсердий. Часть I. Распространенность и факторыриска. Кардиология, 2004; 3:83-86.29. People with diabetes are at higher risk of atrial fibrillation,Published: Thursday, 2010; 18:12 in Health &Medicine.30. Gregory Y. H., Watson T., Shantsila E. Anticoagulationfor stroke prevention in atrial fibrillation: is genderimportant? Euro Heart. J., 2006; 27:1893-1894.31. Fang M.C., Singer DE., Chang Y. et al. Gender differencesin the risk of ischemic stroke and peripheral embolismin atrial fibrillation,(ATRIA) study. Circulation, 2005;112:687–1691.32. Amarenco P., Tonkin A.M. Statins for stroke prevention:disappointment and hope. Circulation., 2004;109:III-44–III-49.33. Marcucci R., Betti I., Cecchi E., et al. Hyperhomocy-steinemiaand vitamin B6 deficiency: new risk markersfor nonvalvular atrial fibrillation? Am. Heart. J. 2004;148:456-61.34. Fontaine K.R., Redden D.T., Wang C. et al. Years oflife lost due to obesity. JAMA. 2003; 289:187–193.35. Sascha Dublin et al. Influence of high body indexto risk of atrial fibrillation and stroke. Arch. Intern. Med.,2007;166:2322-2328.36. Towfighi Amytis et al. NHANES (National Healthand Nutrition Examination Survey) 1999-2004. Neurulogy,2007; advance online publication.37. Conway D.S.G., Buggin P., Hughes E. et al. Relationof interleukin-6, C-reactive protein, and the prothromboticstate to transesophageal echocardiographic findings inatrial fibrillation. Am. J. Cardiol., 2004; 93:1368-1373.38. Д-р F. Purroy и коллеги (УниверситетскаяКлиника Arnau de Villanova, Lleida, Испания).С-реактивный белок предсказывает риск повторныхсосудистых событий. Acta Neurol. Scand., 2007; 15:60-66.39. Koen Putman. Образовательный уровеньинсультных больных определяет ответ нареабилитацию в стационаре, уровень дохода -восстановление после выписки. J. Neurol. Neurosurg.Psychiatry, 2006; advance online publication 25.12.2006.RezumatLucrarea de faţă își propune să analizeze principaliifactori de risc de dezvoltare a accidentelor vascularecerebrale ischemice și impactul lor la bolnavii cu FA,deoarece această patologie este extrem de răspândităși are costuri economico-sociale ridicate. Ictusul esteo afecţiune heterogenă multifactorială, influenţată defactori de risc modificabili și nemodificabili. Factoriide risc modificabili includ anamneza de hipertensiunearterială, diabet zaharat și cardiopatie ischemică. Factoriide risc nemodificabili includ vârsta, genul și rasa.Alţi factori de risc mai puţin documentaţi sunt locali-